EX-99.2 3 a17-12140_1ex99d2.htm EX-99.2

Exhibit 99.2

 

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF INCOME - GAAP

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 1a

 

 

 

2017

 

2016

 

% Change

 

 

 

1Q

 

1Q

 

2Q

 

3Q

 

4Q

 

Full Year

 

1Q

 

Sales

 

$

9,434

 

$

9,312

 

$

9,844

 

$

10,536

 

$

10,115

 

$

39,807

 

1

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Costs, Expenses and Other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Materials and production

 

3,015

 

3,572

 

3,578

 

3,409

 

3,332

 

13,891

 

-16

%

Marketing and administrative

 

2,411

 

2,318

 

2,458

 

2,393

 

2,593

 

9,762

 

4

%

Research and development

 

1,796

 

1,659

 

2,151

 

1,664

 

4,650

 

10,124

 

8

%

Restructuring costs

 

151

 

91

 

134

 

161

 

265

 

651

 

66

%

Other (income) expense, net

 

58

 

48

 

19

 

22

 

631

 

720

 

21

%

Income (Loss) Before Taxes

 

2,003

 

1,624

 

1,504

 

2,887

 

(1,356

)

4,659

 

23

%

Income Tax Provision (Benefit)

 

447

 

494

 

295

 

699

 

(769

)

718

 

 

 

Net Income (Loss)

 

1,556

 

1,130

 

1,209

 

2,188

 

(587

)

3,941

 

38

%

Less: Net Income Attributable to Noncontrolling Interests

 

5

 

5

 

4

 

4

 

7

 

21

 

 

 

Net Income (Loss) Attributable to Merck & Co., Inc.

 

$

1,551

 

$

1,125

 

$

1,205

 

$

2,184

 

$

(594

)

$

3,920

 

38

%

Earnings (Loss) per Common Share Assuming Dilution (1)

 

$

0.56

 

$

0.40

 

$

0.43

 

$

0.78

 

$

(0.22

)

$

1.41

 

40

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Average Shares Outstanding Assuming Dilution (1)

 

2,766

 

2,795

 

2,789

 

2,786

 

2,755

 

2,787

 

 

 

Tax Rate

 

22.3

%

30.4

%

19.6

%

24.2

%

56.7

%

15.4

%

 

 

 

Sum of quarterly amounts may not equal year-to-date amounts due to rounding. 

 

(1) Because the company recorded a net loss in the fourth quarter of 2016, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive.

 



 

MERCK & CO., INC.
GAAP TO NON-GAAP RECONCILIATION
FIRST QUARTER 2016
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2b

 

 

 

GAAP

 

Acquisition and
Divestiture-
Related Costs 
(1)

 

Restructuring
Costs 
(2)

 

Adjustment
Subtotal

 

Non-GAAP

 

Materials and production

 

$

3,572

 

1,386

 

47

 

1,433

 

$

2,139

 

Marketing and administrative

 

2,318

 

2

 

3

 

5

 

2,313

 

Research and development

 

1,659

 

35

 

55

 

90

 

1,569

 

Restructuring costs

 

91

 

 

 

91

 

91

 

 

Other (income) expense, net

 

48

 

 

 

 

 

 

 

48

 

Income Before Taxes

 

1,624

 

(1,423

)

(196

)

(1,619

)

3,243

 

Income Tax Provision (Benefit)

 

494

 

(209

)(3)

(43

)(3)

(252

)

746

 

Net Income

 

1,130

 

(1,214

)

(153

)

(1,367

)

2,497

 

Net Income Attributable to Merck & Co., Inc.

 

1,125

 

(1,214

)

(153

)

(1,367

)

2,492

 

Earnings per Common Share Assuming Dilution

 

$

0.40

 

(0.43

)

(0.06

)

(0.49

)

$

0.89

 

Tax Rate

 

30.4

%

 

 

 

 

 

 

23.0

%

 

Only the line items that are affected by non-GAAP adjustments are shown.

 

Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. Senior management’s annual compensation is derived in part using non-GAAP income and non-GAAP EPS. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.

 

(1) Amounts included in materials and production costs reflect $1.1 billion of expenses for the amortization of intangible assets recognized as a result of acquisitions, as well as $24 million of amortization of purchase accounting adjustments to inventories related to the 2015 acquisition of Cubist Pharmaceuticals, Inc., and $252 million of intangible asset impairment charges. Amounts included in marketing and administrative expenses reflect integration, transaction and certain other costs related to business acquisitions, including severance costs which are not part of the company’s formal restructuring programs, as well as transaction and certain other costs related to business divestitures. Amounts included in research and development expenses primarily reflect in-process research and development (IPR&D) impairment charges.

 

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company’s formal restructuring programs.

 

(3) Represents the estimated tax impact of the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.

 



 

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
FIRST QUARTER 2017
(AMOUNTS IN MILLIONS)
Table 3a

 

 

 

Global

 

U.S.

 

International

 

 

 

1Q 2017

 

1Q 2016

 

% Change

 

1Q 2017

 

1Q 2016

 

% Change

 

1Q 2017

 

1Q 2016

 

% Change

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TOTAL SALES (1)

 

$

9,434

 

$

9,312

 

1

 

$

4,195

 

$

4,222

 

-1

 

$

5,239

 

$

5,090

 

3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

PHARMACEUTICAL

 

8,185

 

8,104

 

1

 

3,761

 

3,913

 

-4

 

4,424

 

4,191

 

6

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Primary Care and Women’s Health

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cardiovascular

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Zetia

 

334

 

612

 

-46

 

111

 

386

 

-71

 

222

 

226

 

-2

 

Vytorin

 

241

 

277

 

-13

 

90

 

109

 

-18

 

151

 

168

 

-10

 

Liptruzet

 

49

 

23

 

114

 

 

 

 

 

 

 

49

 

23

 

114

 

Adempas

 

84

 

33

 

158

 

 

 

 

 

 

 

84

 

33

 

158

 

Diabetes

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Januvia

 

839

 

906

 

-7

 

507

 

549

 

-8

 

332

 

357

 

-7

 

Janumet

 

496

 

506

 

-2

 

195

 

226

 

-14

 

302

 

280

 

8

 

General Medicine & Women’s Health

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Implanon / Nexplanon

 

170

 

134

 

27

 

132

 

99

 

32

 

39

 

35

 

12

 

NuvaRing

 

160

 

175

 

-9

 

113

 

128

 

-12

 

47

 

48

 

-1

 

Follistim AQ

 

81

 

94

 

-14

 

42

 

53

 

-21

 

40

 

42

 

-4

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Hospital and Specialty

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Hepatitis

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Zepatier

 

378

 

50

 

*

 

200

 

49

 

*

 

178

 

1

 

*

 

HIV

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Isentress

 

305

 

340

 

-10

 

143

 

162

 

-12

 

162

 

178

 

-9

 

Hospital Acute Care

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Bridion

 

148

 

90

 

63

 

45

 

5

 

*

 

102

 

86

 

19

 

Noxafil

 

141

 

145

 

-3

 

65

 

71

 

-8

 

76

 

74

 

3

 

Invanz

 

136

 

114

 

20

 

82

 

65

 

26

 

54

 

49

 

10

 

Cancidas

 

121

 

133

 

-9

 

5

 

4

 

20

 

116

 

128

 

-10

 

Cubicin

 

96

 

292

 

-67

 

54

 

255

 

-79

 

41

 

37

 

13

 

Primaxin

 

62

 

73

 

-15

 

 

 

1

 

-57

 

62

 

73

 

-14

 

Immunology

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Remicade

 

229

 

349

 

-34

 

 

 

 

 

 

 

229

 

349

 

-34

 

Simponi

 

184

 

188

 

-2

 

 

 

 

 

 

 

184

 

188

 

-2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Oncology

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Keytruda

 

584

 

249

 

134

 

361

 

133

 

172

 

223

 

116

 

92

 

Emend

 

133

 

126

 

6

 

86

 

82

 

5

 

47

 

44

 

7

 

Temodar

 

66

 

66

 

 

 

1

 

4

 

-78

 

65

 

62

 

6

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diversified Brands

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Respiratory

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Singulair

 

186

 

237

 

-22

 

6

 

17

 

-66

 

180

 

220

 

-18

 

Nasonex

 

139

 

229

 

-40

 

18

 

112

 

-84

 

121

 

117

 

3

 

Dulera

 

82

 

113

 

-27

 

75

 

107

 

-29

 

7

 

6

 

18

 

Other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cozaar / Hyzaar

 

112

 

126

 

-11

 

3

 

6

 

-48

 

109

 

121

 

-9

 

Arcoxia

 

103

 

111

 

-7

 

 

 

 

 

 

 

103

 

111

 

-7

 

Fosamax

 

61

 

75

 

-19

 

1

 

1

 

62

 

60

 

74

 

-20

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vaccines (2)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gardasil / Gardasil 9

 

532

 

378

 

41

 

398

 

320

 

25

 

134

 

58

 

130

 

ProQuad / M-M-R II / Varivax

 

355

 

357

 

 

 

298

 

310

 

-4

 

57

 

47

 

21

 

RotaTeq

 

224

 

188

 

19

 

178

 

149

 

20

 

45

 

39

 

16

 

Pneumovax 23

 

163

 

107

 

52

 

114

 

67

 

70

 

49

 

40

 

22

 

Zostavax

 

154

 

125

 

23

 

109

 

109

 

 

 

45

 

16

 

174

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Pharmaceutical (3)

 

1,037

 

1,083

 

-4

 

329

 

334

 

-1

 

709

 

745

 

-5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANIMAL HEALTH

 

939

 

829

 

13

 

283

 

233

 

22

 

656

 

596

 

10

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Revenues (4)

 

310

 

379

 

-18

 

151

 

76

 

99

 

159

 

303

 

-48

 

 

* 200% or greater

 

(1) Only select products are shown.

 

(2) Vaccine sales in 2017 include sales in the European markets that were previously part of the Sanofi Pasteur MSD (SPMSD) joint venture that was terminated on December 31, 2016. Amounts for 2016 include supply sales to SPMSD.

 

(3) Includes Pharmaceutical products not individually shown above. Other Vaccines sales included in Other Pharmaceutical were $88 million and $103 million on a global basis for first quarter 2017 and 2016, respectively.

 

(4) Other Revenues are comprised primarily of alliance revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.

 



 

MERCK & CO., INC.

PHARMACEUTICAL GEOGRAPHIC SALES

(AMOUNTS IN MILLIONS)

(UNAUDITED)

Table 3b

 

 

 

2017

 

2016

 

% Change

 

 

 

1Q

 

1Q

 

2Q

 

3Q

 

4Q

 

Full Year

 

1Q

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TOTAL PHARMACEUTICAL

 

$

8,185

 

$

8,104

 

$

8,700

 

$

9,443

 

$

8,904

 

$

35,151

 

1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

United States

 

3,761

 

3,913

 

4,169

 

4,710

 

4,282

 

17,073

 

-4

 

% Pharmaceutical Sales

 

45.9

%

48.3

%

47.9

%

49.9

%

48.1

%

48.6

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Europe (1)

 

1,977

 

1,914

 

1,997

 

1,935

 

1,843

 

7,689

 

3

 

% Pharmaceutical Sales

 

24.2

%

23.6

%

23.0

%

20.5

%

20.7

%

21.9

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Japan

 

688

 

620

 

673

 

812

 

659

 

2,764

 

11

 

% Pharmaceutical Sales

 

8.4

%

7.7

%

7.7

%

8.6

%

7.4

%

7.9

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Asia Pacific

 

889

 

806

 

890

 

914

 

912

 

3,522

 

10

 

% Pharmaceutical Sales

 

10.9

%

9.9

%

10.2

%

9.7

%

10.2

%

10.0

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

China

 

328

 

337

 

353

 

350

 

333

 

1,374

 

-3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Latin America

 

375

 

359

 

430

 

448

 

538

 

1,776

 

5

 

% Pharmaceutical Sales

 

4.6

%

4.4

%

4.9

%

4.7

%

6.0

%

5.1

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Eastern Europe/Middle East Africa

 

255

 

272

 

314

 

364

 

429

 

1,379

 

-6

 

% Pharmaceutical Sales

 

3.1

%

3.4

%

3.6

%

3.9

%

4.8

%

3.9

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Canada

 

182

 

147

 

170

 

184

 

180

 

682

 

23

 

% Pharmaceutical Sales

 

2.2

%

1.8

%

2.0

%

1.9

%

2.0

%

1.9

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other

 

58

 

73

 

57

 

76

 

61

 

266

 

-21

 

% Pharmaceutical Sales

 

0.7

%

0.9

%

0.7

%

0.8

%

0.7

%

0.8

%

 

 

 

(1) Europe primarily represents all European Union countries and the European Union accession markets.

 



 

MERCK & CO., INC.

OTHER (INCOME) EXPENSE, NET - GAAP

(AMOUNTS IN MILLIONS)

(UNAUDITED)
Table 4

 

 

OTHER (INCOME) EXPENSE, NET

 

 

 

1Q17

 

1Q16

 

INTEREST INCOME

 

$

(97

)

$

(79

)

INTEREST EXPENSE

 

182

 

172

 

EXCHANGE (GAINS) LOSSES

 

(8

)

38

 

EQUITY LOSS (INCOME) FROM AFFILIATES

 

13

 

(34

)

Other, net

 

(32

)

(49

)

TOTAL

 

$

58

 

$

48